Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer

MT Newswires Live05-24

Regeneron Pharmaceuticals (REGN) said late Thursday that combination therapy of GN7075 and Libtayo, or cemiplimab, led to anti-tumor responses in patients with microsatellite stable colorectal cancer based on data from the dose-escalation portion of an ongoing phase 1/2 trial.

Efficacy results from 51 patients with microsatellite stable colorectal cancer showed a 6% overall response rate and a 29% disease control rate, the drugmaker said.

"Microsatellite stable colorectal cancer has historically been unresponsive to immunotherapy" but the combination therapy showed "anti-tumor responses in a highly difficult-to-treat cancer," according to a trial investigator.

Safety was evaluated in 84 patients across multiple solid tumor types at various doses of REGN7075. Treatment-emergent adverse events of any grade occurred in 98% of patients, while treatment-related adverse events occurred in 90% of patients, the company said.

Price: 982.72, Change: +2.15, Percent Change: +0.22

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment